Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids
PLOS One · 2025
DOI: 10.1371/journal.pone.0326550 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Jonathan Barajas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Surgery and Biomedical Engineering, Keck School of Medicine, University of Southern California, Los Angeles, California, United States…. Hauptthemen laut MEDLINE: Deoxycytidine, Drug Resistance, Neoplasm, Organoids, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Division of Cancer Prevention, National Cancer Institute.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with limited therapeutic advancements and rapid development of treatment resistance. Fatty acid-conjugated gemcitabine analogs have shown improved antitumor efficacy. This study investigates the effects of gemcitabine conjugated with caprylic acid (Gemcitabine-8C) in combination with AZD 1775, a WEE1 inhibitor, using patient-derived PDAC organoids.
Methods
Patient-derived PDAC cells (G43, G46) were cultured in a gelatin-based 3D organoid system with tunable stiffness to mimic the tumor microenvironment. Cells were treated with gemcitabine, Gemcitabine-8C, AZD 1775, or their combination. The study assessed treatment efficacy, extracellular matrix influence, morphology, gene expression, and drug resistance mechanisms.
Results
The combination of AZD 1775 and Gemcitabine-8C significantly enhanced treatment efficacy compared to monotherapies or gemcitabine with AZD 1775. G43 cells were more sensitive to treatment than G46. Increased matrix stiffness correlated with greater drug resistance. Resistant cells exhibited elevated oxidative stress, while sensitive cells showed F-actin structural alterations absent in resistant counterparts.
Conclusions
AZD 1775 enhances the efficacy of Gemcitabine-8C at non-toxic doses, demonstrating its potential for overcoming PDAC treatment resistance. The cell origin and tumor microenvironment plays a key role in modulating drug response, highlighting the need for microenvironment and individualized-targeted strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Surgery and Biomedical Engineering, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
- College of Pharmaceutical Science, Florida A&M University, Tallahassee, Florida, United States of America.
- College of Nursing, University of Florida, Gainesville, Florida, United States of America.
ORCID-Profile: Jonathan Barajas
Förderung
- NCI NIH HHS
- Division of Cancer Prevention, National Cancer Institute
Zitieren
APA
Barajas, J., Yang, Z., Agyare, E., Zhu, X., Yoon, S. J., & Han, B. (2025). Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids. PLOS One. https://doi.org/10.1371/journal.pone.0326550
Vancouver
Barajas J, Yang Z, Agyare E, Zhu X, Yoon SJ, Han B. Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids. PLOS One. 2025. doi:10.1371/journal.pone.0326550
BibTeX
@article{Barajas2025,
author = {Barajas, Jonathan and Yang, Zhi and Agyare, Edward and Zhu, Xueyou and Yoon, Saun-Joo and Han, Bo},
title = {Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0326550}
}
EUVIMED